GLP3/GLP1R
GLP3/GLP1R is a synthetic peptide comprising 39 amino acids. It is engineered to function as a tri-agonist, simultaneously targeting the Glucagon-Like Peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and Glucagon (GCGR) receptors. For Research Use Only. Not for human consumption.
GLP3/GLP1R is a chemically modified peptide with the molecular formula C₂₂₁H₃₄₂N₄₆O₆₈. It is built upon a GIP peptide backbone and contains 39 amino acids. Key structural modifications include the attachment of a C20 fatty diacid moiety, which facilitates binding to albumin and extends the peptide’s stability and half-life in biological solvents. This structure allows the molecule to interact with three distinct G-protein coupled receptors: GLP-1R, GIPR, and GCGR.
Scientific studies focus on the unique “triple agonism” pharmacology of GLP3/GLP1R. While GLP-1 and GIP receptor activation are associated with insulin secretion and satiety signaling, the addition of Glucagon receptor (GCGR) agonism is hypothesized to enhance mitochondrial energy expenditure. In laboratory assays, researchers examine how this simultaneous receptor engagement influences hepatic fatty acid oxidation and basal metabolic rates compared to mono- or dual-agonists.
In murine and primate models, GLP3/GLP1R is utilized to study complex metabolic phenotypes. Data suggests that the inclusion of glucagon signaling may recruit thermogenic pathways in brown adipose tissue and reduce hepatic lipid accumulation. Investigators monitor these pathways to understand the synergistic effects of targeting the incretin axis alongside glucagon-mediated catabolism.
This product is strictly for laboratory and research purposes only. GLP3/GLP1R is not intended for human use, diagnostic, or therapeutic procedures. It serves as a reagent for scientific study and method development.
References
- Coskun, T., et al. (2022). “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell Metabolism, 34(9), 1234-1247.
- Jastreboff, A. M., et al. (2023). “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” The New England Journal of Medicine, 389, 514-526.
- Urva, S., et al. (2022). “The novel GIP, GLP-1 and glucagon receptor agonist Retatrutide delays gastric emptying.” Diabetes, Obesity and Metabolism, 24(11), 2108-2115.